SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment

Blood

Volumn 112, Issue 4, 2008, Pages 1269-1279

  Huang, Bo ^a   Lei, Zhang ^a   Zhang, Gui Mei ^a   Li, Dong ^a   Song, Chuanwang ^a   Li, Bo ^a   Liu, Yanyan ^a   Yuan, Ye ^a   Unkeless, Jay ^b   Xiong, Huabao ^b   Feng, Zuo Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; NUCLEIC ACID BINDING PROTEIN; PROTEIN AP 1; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE EXACERBATION; IMMUNE DEFICIENCY; INFLAMMATION; MAST CELL; MICROENVIRONMENT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CHEMOTAXIS; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MOUSE STRAIN; NEOPLASM; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOTAXIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-17; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MAST CELLS; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NF-KAPPA B; STEM CELL FACTOR; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTION FACTOR AP-1;

EID: 51649123035     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-147033     Document Type: Article

References (55)

1. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.
2. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006; 124:823- 835.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
4. Balkwill F. Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 ;357:539-545.
5. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med. 2001:193:F23- 26.
6. Kinet J P. The essential role of mast cells in orchestrating inflammation. Immunol Rev. 2007; 217:5-7.
7. Metz M. Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304-328.
8. Dabiri S, Huntsman D, Makretsov N, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol. 2004;17:690-695.
9. Rojas IG, Spencer ML, Martinez A, Maurelia MA, Rudolph Ml. Characterization of mast cell sub- populations in lip cancer. J Oral Pathol Med. 2005;34:268-273.
10. Elpek GO, Gelen T, Aksoy NH, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol. 2001 ;54:940-944.
11. Ribatti D, Ennas MG, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003;33:420-425.
12. Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer. 2004;43:47-54.
13. Miettinen M, Lasota J. KIT(CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13: 205-220.
14. LawrenceT. Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci. 2007;28:162- 165.
15. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217.
16. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003:4:605- 615.
17. Kulbe H, Thompson R, Wilson JL et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67:585-592.
18. Lin WW. Karin MA. Cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175-1183.
19. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-360.
20. Ullrich SE, Nghiem DX, Khaskina P. Suppression of an established immune response by UVA-a critical role for mast cells. Photochem Photobiol. 2007;83:1095-1100.
21. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol. 2007; 8:1095-1104.
22. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442:997-1002.
23. MelendezAJ, Harnett MM, Pushparaj PN, et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13:1211-1218.
24. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 2004;25:235-241.
25. Starkey JR, Crowle PK, Taubenberger S. Mast- cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer. 1988;42:48- 52.
26. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006;34:97-115.
27. Nilsson G, Butterfield JH, Nilsson K, et al. Stem cell factor is a chemotactic factor for human mast cells. J Immunol. 1994;153:3717-3723.
28. Fischer M, Juremalm M. Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed- Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer. 2003;107:197-201.
29. Samayawardhena LA, Hu J, Stein PL, et al. Fyn kinase acts upstream of Shp2 and p38 mitogen- activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell Signal. 2006;18:1447-1454.
30. Samayawardhena LA, Kapur R, Craig AW. Involvement of Fyn kinase in Kit and integrin- mediated Rac activation, cytoskeletal reorganization, and chemotaxis of mast cells. Blood. 2007; 109:3679-3686.
31. Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol. 2008;38:489-499.
32. National Center for Biotechnology Information. http://www.ncbi.nlm.nih. gov/entrez?db=nuccore&itool=toolbar. Accessed 2006.
33. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit- ligand. Cell. 2002;109:625-637.
34. Liu Y, Huang B, Yuan Y, et al. Inhibition of hepato-carcinoma and tumor metastasis to liver by gene therapy with recombinant CBD-Hepl I polypeptide of fibronectin. Int J Cancer. 2007;121:184-192.
35. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007; 67:4346-4352.
36. Marquardt DL, Gruber HE, Wasserman SI. Adenosine release from stimulated mast cells. Proc Natl Acad Sci U S A. 1984;81:6192-6196.
37. Di Girolamo N, Indoh I, Jackson N, et al. Human mast cell-derived gelatinase B (matrix metallopro- teinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol. 2006; 177:2638- 2650.
38. Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005; 175:1197-1205.
39. + T cells. J Immunol. 2005;174: 1073-1080.
40. Erdmann AA, Gao ZG, Jung U, et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2- driven expansion in vivo. Blood. 2005;105:4707- 4714.
41. Kalesnikoff J, Rios EJ, Chen CC, et al. Rab- GEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proc Natl Acad Sci USA. 2006; 103:2659-2664.
42. Gooch JL, Lee AV, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 1998;58:4199-4205.
43. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-a/cachectin. Nature. 1990;346:274-276.
44. Fannon M, Forsten-Williams K, Dowd CJ; Freed- man DA, Folkman J, Nugent MA. Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J 2003;17:902-904.
45. Huang B. Zhao J, Li H. et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65:5009-5014.
46. Huang B, Lei Z, Zhao J, et al. GCL2/CGR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007;252:86-92.
47. Kolls JK, Linden A. lnterleukin-17 family members and inflammation. Immunity. 2004;21:467-476.
48. Yu JJ, Gaffen SL. lnterleukin-17: a novel inflamrnatory cytokine that bridges innate and adaptive immunity. Front Biosci. 2008;13:170-177.
49. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy. 2004:34: 1660-1664.
50. Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest. 2004;114:1317- 1325.
51. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947.
52. Ditsworth D, Zong WX. NF-kappaB: key mediator of inflammation-associated cancer. Cancer Biol Ther. 2004:3:1214-1216.
53. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21: 807-839.
54. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
55. + channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur J Immunol. 2007;37:1653-1662.